Stockscreener 앱 받기
0.00
100.00%
-14.16
시간 외 거래:
14.16
14.16
+
전일 마감가:
$14.16
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$883.54M
수익:
-
순이익/손실:
-
주가수익비율:
0.00
EPS:
-1.0062
순현금흐름:
-
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$14.77
52주 변동 폭
$0.00
$17.25
Adlai Nortye Ltd Adr Stock (ANL) Company Profile
Compare ANL vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANL
Adlai Nortye Ltd Adr
|
0.00 | 883.54M | 0 | 0 | 0 | -1.0062 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Adlai Nortye Ltd Adr Stock (ANL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-20 | 개시 | Leerink Partners | Outperform |
| 2026-02-13 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-06-02 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-09-04 | 개시 | H.C. Wainwright | Buy |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
Adlai Nortye Ltd Adr 주식(ANL)의 최신 뉴스
Adlai Nortye Redomiciles to Singapore and Updates Nasdaq Identity - TipRanks
Wall Street Analysts See an 81.78% Upside in Adlai Nortye Ltd. Sponsored ADR (ANL): Can the Stock Really Move This High? - Yahoo Finance
HC Wainwright Increases Earnings Estimates for Adlai Nortye - MarketBeat
Adlai Nortye (NASDAQ:ANL) Stock Price Up 6.2%Still a Buy? - MarketBeat
Adlai Nortye Boosts Cash Reserves and Advances RAS-Focused Oncology Pipeline in First Half of 2026 - TipRanks
Adlai Nortye (ANL) Earnings Date and Reports 2026 $ANL - MarketBeat
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Adlai Nortye (ANL) Sheds 0.75% to $13.18 as Biotech ADR Holds Above Key SupportMoney Flow Index - dars.gov.et
Adlai Nortye Initiated at Buy as First-in-Class RASiCA ADC Enters Clinic; $20 Price Target Reiterated - TipRanks
Adlai Nortye receives approval to begin trial in Australia - Investing.com
Adlai Nortye Wins Australian Clearance to Launch First-in-Class Pan-RAS(ON) ADC Trial - TipRanks
ADAR1 Capital Management LLC Makes New $816,000 Investment in Adlai Nortye Ltd. Sponsored ADR $ANL - MarketBeat
Affinity Asset Advisors LLC Takes Position in Adlai Nortye Ltd. Sponsored ADR $ANL - MarketBeat
Adlai Nortye Ltd. Sponsored ADR (ANL) Receives a Buy from Cantor Fitzgerald - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Harmony Biosciences Holdings (HRMY) and Adlai Nortye Ltd. Sponsored ADR (ANL) - The Globe and Mail
Adlai Nortye Begins Weekly Dosing Arm in Global Phase 1 Trial of RAS Inhibitor AN9025 - TipRanks
Analysts Are Bullish on Top Healthcare Stocks: Fractyl Health, Inc. (GUTS), AbbVie (ABBV) - The Globe and Mail
Adlai Nortye: Buy Rating Reaffirmed as Dual-Arm AN9025 Strategy Advances; $20 Price Target Maintained - TipRanks
Adlai Nortye doses first patient in weekly trial arm of AN9025 - Investing.com
Adlai Nortye expands scientific advisory board with two oncologists By Investing.com - Investing.com Nigeria
Adlai Nortye expands scientific advisory board with two oncologists - Investing.com
Enterprise value to EBITDA forward of Adlai Nortye Ltd. Sponsored ADR – SWB:N2U0 - TradingView
Price to sales forward of Adlai Nortye Ltd. Sponsored ADR – FWB:N2U0 - TradingView
Enterprise value to EBIT forward of Adlai Nortye Ltd. Sponsored ADR – FWB:N2U0 - TradingView
Enterprise value to EBITDA forward of Adlai Nortye Ltd. Sponsored ADR – FWB:N2U0 - TradingView
Adlai Nortye Ltd. Sponsored ADR Actuals & Estimates (NASDAQ:ANL) - TradingView
Enterprise value to revenue forward of Adlai Nortye Ltd. Sponsored ADR – FWB:N2U0 - TradingView
Cantor Fitzgerald initiates Adlai Nortye stock with overweight rating By Investing.com - Investing.com Nigeria
Cantor Fitzgerald initiates Adlai Nortye stock with overweight rating - Investing.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: CVRx (CVRX) and Context Therapeutics (CNTX) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Rezolute (RZLT), Relay Therapeutics (RLAY) - The Globe and Mail
ANL Stock Price, Quote & Chart | ADLAI NORTYE LTD-ADR (NASDAQ:ANL) - ChartMill
Adlai Nortye initiated with an Outperform at Oppenheimer - TipRanks
Oppenheimer initiates Adlai Nortye stock coverage with Outperform By Investing.com - Investing.com Nigeria
Oppenheimer initiates Adlai Nortye stock coverage with Outperform - Investing.com
ANLAdlai Nortye Ltd ADR Stock Price and Quote - Finviz
Adlai Nortye Ltd. sponsored ADR (ANL) upgraded to buy: Here's what you should know - MSN
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Bicara Therapeutics Inc. (BCAX) - The Globe and Mail
Adlai Nortye CEO Lu Yang sells $131 in company stock By Investing.com - Investing.com Australia
Adlai Nortye CEO Lu Yang sells $131 in company stock - Investing.com
Adlai Nortye initiated with a Buy at JonesResearch - TipRanks
Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Analysts Are Bullish on These Healthcare Stocks: Aquestive Therapeutics (AQST), Monopar Therapeutics Inc (MNPR) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Adlai Nortye Ltd. Sponsored ADR (ANL), Protagonist Therapeutics (PTGX) and Nuvalent (NUVL) - The Globe and Mail
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year? - Yahoo Finance
Here's why Adlai Nortye Ltd. sponsored ADR (ANL) is a great 'buy the bottom' stock now - MSN
Here's Why Adlai Nortye Ltd. Sponsored ADR (ANL) Is a Great 'Buy the Bottom' Stock Now - Yahoo! Finance Canada
H.C. Wainwright Sees “Potential Best-in-Class Potency” for Adlai Nortye’s (ANL) Lead Asset, Lifts PT - Yahoo Finance
Adlai Nortye (NASDAQ:ANL) Trading 12.3% HigherHere's Why - MarketBeat
Adlai Nortye Ltd Adr (ANL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.00%
3.22%
자본화:
|
볼륨(24시간):